MC
UBX

Mayo Clinic’s Unity Biotechnology UBX Stock Holding History

Mayo Clinic’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$182K Hold
124,081
– – 6.29% 3
2024
Q2 		$168K Hold
124,081
– – 5.53% 3
2024
Q1 		$203K Hold
124,081
– – 3.31% 5
2023
Q4 		$239K Hold
124,081
– – 1.48% 5
2023
Q3 		$298K Hold
124,081
– – 0.57% 4
2023
Q2 		$316K Sell
124,081
-33,117
-21% -$87.5K 0.32% 5
2023
Q1 		$256K Hold
157,198
– – 0.21% 9
2022
Q4 		$431K Buy
+157,198
New +$457K 0.23% 6
2021
Q2 		$7.29M Hold
157,198
– – 8.07% 3
2021
Q1 		$9.43M Hold
157,198
– – 10.86% 3
2020
Q4 		$8.24M Hold
157,198
– – 9.91% 3
2020
Q3 		$5.44M Hold
157,198
– – 7.33% 4
2020
Q2 		$13.6M Hold
157,198
– – 13.06% 4
2020
Q1 		$9.12M Hold
157,198
– – 23.05% 2
2019
Q4 		$11.3M Buy
+157,198
New +$11.1M 12.85% 2

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.3B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.37B AUM 63.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $7.18B AUM 21.21% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return